Unknown

Dataset Information

0

Effect of folylpolyglutamate synthase A22G polymorphism on the risk and survival of patients with acute lymphoblastic leukemia.


ABSTRACT: Folylpolyglutamate synthase (FPGS) is the key enzyme that converts the chemotherapeutic agent, methotrexate (MTX), into MTX polyglutamate. An A22G polymorphism has been found in the FPGS gene. This study aimed to evaluated whether the A22G polymorphism in the FPGS gene is associated with an increased risk of acute lymphoblastic leukemia (ALL) and whether it plays a role in increasing the survival of patients with ALL. In this study, a total of 70 patients with ALL and 100 healthy individuals were genotyped by polymerase chain reaction and sequencing methods. The homozygous variant, 22G/G [odds ratio (OR)=3.88; 95% confidence interval (CI): 2.50-6.03] and the heterozygous variant, 22A/G (OR=1.37; 95% CI: 1.26-48.95) were risk factors for ALL. Patients with the 22A/G genotype had an OR of 1.81 (95% CI: 1.57-5.74; P=0.049) and carriers of the 22G/G genotype had an OR of 2.44 (95% CI: 2.40-11.82; P=0.017) for relapse. A significant association between the A22G polymorphism and survival of patients with ALL was found (P<0.05); whereas, individuals with A/G or G/G genotypes had a decreased overall survival (log-rank test, P=0.044). Although preliminary, these data suggest that the genotypes of the A22G polymorphism may be risk factors for ALL and may play a role in the survival of patients with ALL.

SUBMITTER: Gomez-Gomez Y 

PROVIDER: S-EPMC4081359 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effect of folylpolyglutamate synthase A22G polymorphism on the risk and survival of patients with acute lymphoblastic leukemia.

Gómez-Gómez Yazmín Y   Organista-Nava Jorge J   Organista-Nava Jorge J   Rangel-Rodriguez Carlos Alberto CA   Illades-Aguiar Berenice B   Moreno-Godínez María Elena ME   Alarcón-Romero Luz Del Carmen LD   Leyva-Vázquez Marco Antonio MA  

Oncology letters 20140526 2


Folylpolyglutamate synthase (FPGS) is the key enzyme that converts the chemotherapeutic agent, methotrexate (MTX), into MTX polyglutamate. An A22G polymorphism has been found in the FPGS gene. This study aimed to evaluated whether the A22G polymorphism in the FPGS gene is associated with an increased risk of acute lymphoblastic leukemia (ALL) and whether it plays a role in increasing the survival of patients with ALL. In this study, a total of 70 patients with ALL and 100 healthy individuals wer  ...[more]

Similar Datasets

| S-EPMC6331679 | biostudies-literature
| S-EPMC5189722 | biostudies-literature
| S-EPMC9480578 | biostudies-literature
| S-EPMC3454425 | biostudies-literature
| S-EPMC2814411 | biostudies-literature
| S-EPMC5494224 | biostudies-literature
| S-EPMC5319533 | biostudies-literature
| S-EPMC2930948 | biostudies-literature
| S-EPMC3538327 | biostudies-literature